Literature DB >> 29748919

Severe Atopic Dermatitis in Children.

Evie Huang1, Peck Y Ong2.   

Abstract

PURPOSE OF REVIEW: Severe atopic dermatitis (AD) in childhood leads to significant morbidity including psychosocial problems and infectious complications. There are only a few approved treatment options for these patients. These include topical corticosteroids and tacrolimus ointment, which are associated with potential side effects. RECENT
FINDINGS: In order to find better and safer treatments, further understanding of AD mechanisms is needed. Primary skin barrier defects play an important role in the pathogenesis of AD. In addition, the suppression of skin barrier functions by Th2 inflammation also plays an important role in the persistence and recurrence of AD. Cytokines in the Th2 pathway, which includes IL-4, IL-13, TSLP, IL-25, IL-31, and IL-33, are potential therapeutic targets in AD. Other potential targets of AD are Janus kinase, phospholipase A2, aryl hydrocarbon receptor, and skin microbiota. A better understanding of the pathogenesis of AD will provide future direction for treatment.

Entities:  

Keywords:  Eczema; Microbiome; Pathogenesis; Pediatric; S. aureus; Therapy

Mesh:

Year:  2018        PMID: 29748919     DOI: 10.1007/s11882-018-0788-4

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  45 in total

Review 1.  The socioeconomic impact of atopic dermatitis in the United States: a systematic review.

Authors:  Anthony J Mancini; Kellee Kaulback; Sarah L Chamlin
Journal:  Pediatr Dermatol       Date:  2008 Jan-Feb       Impact factor: 1.588

2.  Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Authors:  Andrew Blauvelt; Marjolein de Bruin-Weller; Melinda Gooderham; Jennifer C Cather; Jamie Weisman; David Pariser; Eric L Simpson; Kim A Papp; H Chih-Ho Hong; Diana Rubel; Peter Foley; Errol Prens; Christopher E M Griffiths; Takafumi Etoh; Pedro Herranz Pinto; Ramon M Pujol; Jacek C Szepietowski; Karel Ettler; Lajos Kemény; Xiaoping Zhu; Bolanle Akinlade; Thomas Hultsch; Vera Mastey; Abhijit Gadkari; Laurent Eckert; Nikhil Amin; Neil M H Graham; Gianluca Pirozzi; Neil Stahl; George D Yancopoulos; Brad Shumel
Journal:  Lancet       Date:  2017-05-04       Impact factor: 79.321

3.  Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Authors:  Amy S Paller; Wynnis L Tom; Mark G Lebwohl; Robin L Blumenthal; Mark Boguniewicz; Robert S Call; Lawrence F Eichenfield; Douglass W Forsha; William C Rees; Eric L Simpson; Mary C Spellman; Linda F Stein Gold; Andrea L Zaenglein; Matilda H Hughes; Lee T Zane; Adelaide A Hebert
Journal:  J Am Acad Dermatol       Date:  2016-07-11       Impact factor: 11.527

Review 4.  Wet Wrap Therapy in Moderate to Severe Atopic Dermatitis.

Authors:  Noreen Heer Nicol; Mark Boguniewicz
Journal:  Immunol Allergy Clin North Am       Date:  2016-11-01       Impact factor: 3.479

5.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis.

Authors:  Peck Y Ong; Takaaki Ohtake; Corinne Brandt; Ian Strickland; Mark Boguniewicz; Tomas Ganz; Richard L Gallo; Donald Y M Leung
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

6.  Dose-dependent role of claudin-1 in vivo in orchestrating features of atopic dermatitis.

Authors:  Reitaro Tokumasu; Kosuke Yamaga; Yuji Yamazaki; Hiroyuki Murota; Koya Suzuki; Atsushi Tamura; Kana Bando; Yasuhide Furuta; Ichiro Katayama; Sachiko Tsukita
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-24       Impact factor: 11.205

Review 7.  Systemic Agents for Severe Atopic Dermatitis in Children.

Authors:  Eliza R Notaro; Robert Sidbury
Journal:  Paediatr Drugs       Date:  2015-12       Impact factor: 3.022

8.  Staphylococcus aureus Exploits Epidermal Barrier Defects in Atopic Dermatitis to Trigger Cytokine Expression.

Authors:  Teruaki Nakatsuji; Tiffany H Chen; Aimee M Two; Kimberly A Chun; Saisindhu Narala; Raif S Geha; Tissa R Hata; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2016-07-02       Impact factor: 8.551

9.  A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis.

Authors:  Maryam Salimi; Jillian L Barlow; Sean P Saunders; Luzheng Xue; Danuta Gutowska-Owsiak; Xinwen Wang; Li-Chieh Huang; David Johnson; Seth T Scanlon; Andrew N J McKenzie; Padraic G Fallon; Graham S Ogg
Journal:  J Exp Med       Date:  2013-12-09       Impact factor: 14.307

10.  The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation.

Authors:  Christoph S N Klose; Tanel Mahlakõiv; Jesper B Moeller; Lucille C Rankin; Anne-Laure Flamar; Hiroki Kabata; Laurel A Monticelli; Saya Moriyama; Gregory Garbès Putzel; Nikolai Rakhilin; Xiling Shen; Evi Kostenis; Gabriele M König; Takashi Senda; Dustin Carpenter; Donna L Farber; David Artis
Journal:  Nature       Date:  2017-09-06       Impact factor: 49.962

View more
  6 in total

Review 1.  Probing the Skin-Brain Axis: New Vistas Using Mouse Models.

Authors:  Aliće Weiglein; Evelyn Gaffal; Anne Albrecht
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

2.  Childhood atopic dermatitis: current developments, treatment approaches, and future expectations

Authors:  Pınar Gür Çetinkaya; Ümit Murat Şahiner
Journal:  Turk J Med Sci       Date:  2019-08-08       Impact factor: 0.973

3.  Skin manifestations in pediatric patients with primary immunodeficiency diseases (PIDs) in a tertiary care hospital in Colombia.

Authors:  William López-Quintero; Daniela Cleves; Jose David Gomez-Vasco; Paola Pérez; Jaime Patiño; Diego Medina-Valencia; Harry Pachajoa; Laura Torres-Canchala; Andres Vidal; Manuela Olaya
Journal:  World Allergy Organ J       Date:  2021-03-01       Impact factor: 4.084

Review 4.  Flare management in atopic dermatitis: from definition to treatment.

Authors:  Giampiero Girolomoni; Valentina Maria Busà
Journal:  Ther Adv Chronic Dis       Date:  2022-01-13       Impact factor: 5.091

5.  Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis.

Authors:  Ling Liu; Pengxiang Zhou; Zhenhuan Wang; Suodi Zhai; Wei Zhou
Journal:  Front Pediatr       Date:  2022-03-15       Impact factor: 3.418

6.  What plays a role in the severity of atopic dermatitis in children?

Authors:  Murat Cansever; Çiğdem Oruç
Journal:  Turk J Med Sci       Date:  2021-10-21       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.